Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
OSE Immunotherapeutics S.A. (OSE.PA)
Nantes, FR
Based in Nantes, France, OSE Immunotherapeutics S.A. specializes in creating immunotherapies designed to activate or regulate the immune system. Their work primarily targets both immuno-oncology and autoimmune diseases. Their advanced pipeline features Tedopi, which is currently in Phase III clinical trials for non-small cell lung cancer, with further Phase II investigations ongoing for pancreatic and ovarian cancers. For infectious diseases, they are developing CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus. In oncology, their portfolio also includes BI 765063, in Phase I for solid tumors, and BiCKI, an innovative bispecific checkpoint inhibitor platform. BiCKI is engineered to counteract cancer's primary and secondary resistance mechanisms by targeting PD-1 alongside other novel pathways. Addressing autoimmune and inflammatory conditions, OSE Immunotherapeutics is progressing OSE-127, a humanized monoclonal antibody in Phase II trials for both ulcerative colitis and Sjögren's Syndrome. FR104 is undergoing Phase I development for rheumatoid arthritis, while OSE-230, an agonist antibody against ChemR23, aims to resolve chronic inflammation. The company maintains strategic collaborations and partnerships with organizations such as GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. OSE Immunotherapeutics S.A. was formerly known as OSE Pharma SA until its name change in May 2016.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.21% | +8.79% | +38.78% | -0.92% | -24.17% | -15.92% | -27.47% | +14.25% | -59.15% | -33.38% | -58.56% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-96.3% Q4'25: +47.0% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-198.3% Q4'25: -87.0% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,619.2% Q4'25: -1,408.8% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-1,615.4% Q4'25: -1,706.0% (vs Q4'23)
-
ROIC Biotechnology: -16.1%—
-
Share dilution Biotechnology: -3.4%+2.3% ★ Q4'25: +9.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×— Q4'25: -0.44× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
383.0K
est: 7.66M (-95.0%)
|
6.68M
est: 3.34M (+100.0%)
|
24.46M
est: 21.00M (+16.5%)
|
25.95M
est: 19.73M (+31.6%)
|
10.42M
est: 20.38M (-48.9%)
|
26.31M
est: 19.49M (+35.0%)
|
18.30M
est: 19.90M (-8.0%)
|
2.23M
est: 83.44M (-97.3%)
|
69.88M
est: 95.33M (-26.7%)
|
2.60M
est: 18.46M (-85.9%)
|
8.94M
1.55M – 21.64M
-51.6% YoY
|
13.03M
2.25M – 31.54M
+45.7% YoY
|
113.65M
19.65M – 275.12M
+772.2% YoY
|
| EBITDA |
15.31M
est: -4.06M (+477.2%)
|
-12.54M
est: -1.77M (-608.6%)
|
5.01M
est: -11.12M (+145.0%)
|
-989.0K
est: -10.45M (+90.5%)
|
-18.24M
est: -10.79M (-69.0%)
|
-13.72M
est: -10.32M (-32.9%)
|
-13.11M
est: -10.54M (-24.4%)
|
-17.50M
est: -44.20M (+60.4%)
|
41.20M
est: -50.49M (+181.6%)
|
-42.00M
est: -9.78M (-329.5%)
|
-4.74M
-11.46M – -818.8K
+51.6% YoY
|
-6.90M
-16.71M – -1.19M
-45.7% YoY
|
-60.20M
-145.73M – -10.41M
-772.2% YoY
|
| EBIT |
15.30M
est: -4.59M (+433.6%)
|
-12.63M
est: -2.00M (-531.5%)
|
4.89M
est: -12.57M (+138.9%)
|
-1.47M
est: -11.80M (+87.5%)
|
-18.99M
est: -12.19M (-55.7%)
|
-16.38M
est: -11.66M (-40.4%)
|
-16.65M
est: -11.91M (-39.8%)
|
-21.03M
est: -49.93M (+57.9%)
|
37.83M
est: -57.04M (+166.3%)
|
-42.00M
est: -11.05M (-280.2%)
|
-5.35M
-12.95M – -925.0K
+51.6% YoY
|
-7.80M
-18.87M – -1.35M
-45.7% YoY
|
-68.01M
-164.63M – -11.76M
-772.2% YoY
|
| Net Income |
20.67M
est: 14.96M (+38.2%)
|
-10.50M
est: -8.97M (-17.0%)
|
5.49M
est: -2.78M (+297.7%)
|
-4.65M
est: -3.91M (-19.1%)
|
-16.56M
est: -8.35M (-98.3%)
|
-16.85M
est: -19.54M (+13.8%)
|
-17.76M
est: -27.64M (+35.7%)
|
-23.00M
est: 46.03M (-150.0%)
|
37.45M
est: 60.17M (-37.8%)
|
-37.70M
est: -32.52M (-15.9%)
|
-24.28M
-35.14M – -7.69M
+25.3% YoY
|
-19.87M
-43.45M – 3.71M
+18.2% YoY
|
161.70M
-4.98M – 188.31M
+913.7% YoY
|
| SGA |
3.45M
est: 8.25M (-58.2%)
|
4.65M
est: 3.60M (+29.3%)
|
4.40M
est: 22.61M (-80.5%)
|
5.72M
est: 21.24M (-73.1%)
|
6.98M
est: 21.93M (-68.2%)
|
12.28M
est: 20.98M (-41.5%)
|
9.72M
est: 21.42M (-54.6%)
|
8.00M
est: 89.83M (-91.1%)
|
8.66M
est: 102.62M (-91.6%)
|
10.70M
est: 19.87M (-46.2%)
|
9.62M
1.66M – 23.30M
-51.6% YoY
|
14.03M
2.43M – 33.96M
+45.7% YoY
|
122.35M
21.16M – 296.18M
+772.2% YoY
|
| EPS |
1.65
est: 0.69 (+140.6%)
|
-0.73
est: -0.41 (-77.4%)
|
0.35
est: -0.13 (+374.8%)
|
-0.31
est: -0.18 (-73.1%)
|
-1.06
est: -0.38 (-176.9%)
|
-0.93
est: -0.90 (-3.8%)
|
-0.96
est: -0.87 (-11.0%)
|
-1.18
est: 2.18 (-154.2%)
|
1.72
est: 2.67 (-35.6%)
|
-1.69
est: -0.61 (-175.9%)
|
-1.09
-1.58 – -0.34
-77.7% YoY
|
-1.11
-1.95 – 0.17
-1.7% YoY
|
2.97
-0.22 – 8.44
+367.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap ETF DFIS | 0.00% | 25.2K | 0.39% |
| 2 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 36.9K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Nicolas Poirier | Chief Scientific Officer & Director | 478.0K | — |
| Anne-Laure Autret-Cornet | Administrative & Financial Director and Employee Shareholder Representative Director | 21.3K | female |
| Bérangère Vasseur | Chief Medical Officer Immuno-Oncology | — | — |
| Fiona Olivier | Chief Corporate Affairs & Investor Relations Officer | — | female |
| Jean-Jacques Mention | Chief Business Officer | — | male |
| Julien Perrier | Chief Commercial Officer | — | male |
| Linda Lebon | Chief Regulatory Officer | — | female |
| Marc Le Bozec | Chief Executive Officer & Director | — | male |
| Silvia Comis | Chief Clinical & Medical Research Officer | — | — |
| Alain Chatelin | Medical Director | — | — |
| Thomas Gidoin | Deputy CEO & CFO | — | male |
| Aurore Morello | Chief Scientific Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OSE.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
